The protein tyrosine kinase focal adhesion kinase (FAK) plays critical roles in regulating cell growth and survival.25–27 FAK has been evaluated as a therapeutic target for cancer therapy, and several FAK inhibitors are currently in phase II clinical trials for resistant non-small cell lung cancer. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.